ONO‐7475, an Axl‐Mertk dual‐target inhibitor, has demonstrated the capability to overcome Venetoclax resistance in FLT3‐ITD mutant acute myeloid leukemia (AML).[242] Additionally, drugs like AVB‐S6‐500 (Batiraxcept),[243] MRX‐2843,[244] PF‐07265807,[245] and others targeting the “eat me” signal have displayed favorable efficacy in treating different types of cancers. Here, FLT3 is linked to acute myeloid leukemia.